AGENCY AGREEMENTAgency Agreement • January 28th, 2020 • IntelGenx Technologies Corp. • Pharmaceutical preparations
The undersigned, Echelon Wealth Partners Inc. (the “Agent”) understands that IntelGenx Technologies Corp. (the “Corporation”) proposes to issue and offer for sale up to an aggregate amount of 20,000,000 units of the Corporation (each, an “Offered Unit” and collectively, the “Offered Units”) at the purchase price of $0.50 per Offered Unit (the “Offering Price”) for minimum aggregate gross proceeds to the Corporation of $5,000,000 (“Minimum Offering”) and maximum aggregate gross proceeds of $10,000,000 (the “Offering”). Each Offered Unit will be comprised of one share of common stock (a “Common Share”) of the Corporation, and one Common share purchase warrant (each, a “Warrant” and the Common Shares underlying the Warrants, the “Warrant Shares”). Each Warrant entitles the holder thereof to acquire one Common Share for an exercise price of $0.75 per Common Share (the “Exercise Price”) for a period of 36 months following the Closing Date.
COMMON STOCK NON-TRANSFERABLE PURCHASE WARRANT INTELGENX TECHNOLOGIES CORP.IntelGenx Technologies Corp. • January 28th, 2020 • Pharmaceutical preparations • Delaware
THIS COMMON STOCK PURCHASE WARRANT (the "Warrant") certifies that, for value received, ● (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the "Initial Exercise Date") and on or prior to 5:00 p.m. (Montreal time) on ● (the "Termination Date") but not thereafter, to subscribe for and purchase from IntelGenx Technologies Corp., a Delaware corporation (the "Company"), up to ● shares (as subject to adjustment hereunder, the "Warrant Shares") of the Company's common stock (the "Common Stock"). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
